Thinking of Stopping Hormone-Blocking Therapy for Breast Cancer? What to Consider Before You Decide

If you are taking hormone-blocking therapy for breast cancer and are thinking about stopping, you are not alone.

For some people, these medications are relatively easy to tolerate. For others, side effects can significantly affect daily life. Joint pain, hot flashes, fatigue, vaginal dryness, painful intercourse, recurrent urinary tract infections, hair thinning, bone loss, and changes in body composition can make years of treatment feel overwhelming.

It is understandable to wonder:

“Do I really need to keep taking this?”

The answer depends on why you are taking hormone-blocking therapy, your original risk of recurrence, how much benefit the medication is expected to provide, and how much it is affecting your quality of life.

Before deciding to stop altogether, it is important to understand what the medication is doing—and what other options may be available.

What Is Hormone-Blocking Therapy?

Approximately 70% of breast cancers are hormone receptor-positive, meaning the cancer cells contain estrogen receptors (ER), progesterone receptors (PR), or both.

Estrogen can act as a growth signal for these cancers.

Hormone-blocking therapy—also called endocrine therapy or hormone therapy—is designed to interfere with that signal.

Common medications include the three aromatase inhibitors:

Letrozole (Femara)
Anastrozole (Arimidex)
Exemestane (Aromasin)

Another commonly used endocrine therapy is tamoxifen.

Aromatase inhibitors dramatically reduce estrogen production outside of the ovaries and are generally preferred for postmenopausal patients when appropriate. Tamoxifen works differently by blocking estrogen’s effects on breast cancer cells.

Premenopausal patients who take an aromatase inhibitor also require ovarian function suppression, typically with medications such as leuprolide (Lupron) or goserelin (Zoladex), or through surgical removal of the ovaries.

For some patients with higher-risk early-stage breast cancer or metastatic breast cancer, endocrine therapy may also be combined with a CDK4/6 inhibitor. These medications include abemaciclib (Verzenio), ribociclib (Kisqali), and palbociclib (Ibrance), depending on the clinical setting.

Why Are You Taking Hormone-Blocking Therapy?

Before thinking about stopping endocrine therapy, one of the most important questions is:

What is the goal of my treatment?

The answer is very different for someone with stages I–III breast cancer who currently has no evidence of disease compared with someone living with metastatic, or stage IV, breast cancer.

Stage IV Breast Cancer: Treatment Is Generally Continuous

Stage IV breast cancer means the cancer has spread beyond the breast and regional lymph nodes to a distant part of the body, such as the bones, liver, lungs, or brain.

Because metastatic breast cancer remains present somewhere in the body, ongoing systemic treatment is generally necessary to keep the disease under control.

For hormone receptor-positive, HER2-negative metastatic breast cancer, endocrine-based therapy is frequently used as first-line treatment when appropriate. An aromatase inhibitor is generally favored over tamoxifen in this setting and is commonly combined with a CDK4/6 inhibitor.

Unlike endocrine therapy given after treatment for early-stage breast cancer, there usually isn’t a predetermined five- or ten-year stopping point.

Treatment generally continues as long as it is controlling the cancer and the side effects remain acceptable. If the cancer eventually progresses, the treatment is typically changed to another therapy rather than simply stopping cancer treatment altogether.

For someone with stage IV disease, therefore, stopping endocrine therapy without transitioning to another effective treatment is generally not recommended.

Stages I–III: The Goal Is Different

The situation is very different after treatment for stages I–III hormone receptor-positive breast cancer.

You may have completed definitive surgery, radiation when indicated, and chemotherapy when needed. Your scans and examinations may show no evidence of disease (NED), sometimes also described as being in remission.

At this point, it can be natural to wonder why you still need to take a cancer medication every day.

The reason is that endocrine therapy is being used to reduce the risk of breast cancer returning.

Even after the original cancer has been completely removed, microscopic cancer cells can sometimes remain somewhere in the body without being detectable by scans or blood tests.

Endocrine therapy helps reduce the chance that those cells will eventually grow into a detectable recurrence.

A recurrence can happen locally, meaning in the breast, chest wall, or nearby area.

Or it can occur somewhere else in the body, called a distant or metastatic recurrence.

The purpose of years of endocrine therapy is to lower both of these risks.

What About DCIS?

Hormone-blocking therapy may also be recommended after treatment for estrogen receptor-positive ductal carcinoma in situ (DCIS), or stage 0 breast cancer.

The goal in DCIS is somewhat different.

Endocrine therapy can reduce the risk of another breast cancer event in the treated breast and reduce the chance of developing a new hormone receptor-positive breast cancer in the opposite breast.

Unlike invasive breast cancer, endocrine therapy for DCIS has not been shown to improve survival, since survival after DCIS is already excellent.

When endocrine therapy is chosen for DCIS, treatment is commonly recommended for about five years.

How Long Do I Need to Take Hormone-Blocking Therapy?

For invasive stages I–III hormone receptor-positive breast cancer, endocrine therapy is generally taken for years—not months.

Five years is a common starting point, but some patients benefit from extended therapy approaching seven to ten years.

Patients with higher-risk disease, including some people with lymph node-positive breast cancer, are more likely to be considered for longer treatment.

This does not mean that everyone with lymph node-positive disease automatically needs ten years, or that everyone with lymph node-negative disease should stop at five.

Duration is an individualized decision between you and your oncology team.

The important concept is that endocrine therapy is designed to work over a long period of time.

The benefit accumulates with continued treatment. Taking endocrine therapy for only a few months does not provide the same protection as completing years of recommended therapy.

ER+ Breast Cancer Can Recur Many Years Later

One particularly important characteristic of estrogen receptor-positive breast cancer is its potential for late recurrence.

Unlike some breast cancers in which recurrence risk is concentrated more heavily in the first several years, ER+ breast cancer can recur more than 10 years—and sometimes decades—after the original diagnosis.

That matters when considering how long endocrine therapy should be taken.

For someone who has a life expectancy of another 20, 30, or 40 years, simply asking, “What is my risk over the next five years?” may not tell the whole story.

It may also be useful to ask:

“What is my longer-term risk of recurrence?”

That discussion can help you and your oncologist decide whether extended endocrine therapy may provide meaningful additional benefit.

Why Do People Consider Stopping?

The difficulty is that lowering estrogen throughout the body can have consequences far beyond the breast.

Common problems with aromatase inhibitors can include:

Joint and muscle pain
Bone loss, osteopenia, or osteoporosis
Hot flashes and night sweats
Vaginal dryness and atrophic changes
Pain with intercourse
Urinary symptoms or recurrent urinary tract infections
Hair thinning
Fatigue
Changes in body composition
Sleep or mood changes

Tamoxifen has a different side-effect profile, and some patients tolerate it better than an aromatase inhibitor, while others do not.

When these symptoms accumulate over months or years, it is easy to understand why someone might reach a point where they say, “I can’t do this anymore.”

Before You Stop, Find Out How Much the Medication Is Helping You

Not every person receives the same absolute benefit from endocrine therapy.

This is one of the most important points to understand.

Imagine one person has a relatively high baseline risk of recurrence and endocrine therapy substantially reduces that risk. For that person, continuing treatment may provide a large absolute benefit.

Someone else may have had a very small, low-grade, node-negative tumor and have a much lower baseline risk. Even though endocrine therapy still reduces recurrence risk, the absolute benefit may be considerably smaller.

Rather than asking only:

“Does this medication reduce recurrence?”

Ask your oncology team:

“What is my estimated risk of recurrence with endocrine therapy versus without it?”

That is a much more useful question.

When possible, work with your provider to understand both your short-term and long-term risk and the estimated absolute benefit you are receiving from treatment.

Stopping the Medication May Help the Side Effects—but It Also Removes Some of the Protection

This is the tradeoff.

Stopping endocrine therapy may improve medication-related symptoms and quality of life.

But the medication was prescribed for a reason: to reduce the chance that the breast cancer will return.

And recurrence is not simply a laboratory number.

A local recurrence may mean another biopsy, additional surgery, radiation in selected circumstances, or additional systemic treatment.

A distant recurrence means the breast cancer has become metastatic and generally requires ongoing treatment.

There is also an emotional cost that can be difficult to quantify: facing cancer again after believing that chapter of your life was behind you.

One question I sometimes encourage patients to consider is:

“If my cancer were to recur in the future, how would I feel about my decision to stop today?”

That question is not intended to frighten or guilt anyone into taking a medication.

It is meant to help make sure that the decision you make today is one you understand and can feel comfortable with later.

Before You Quit, Consider a Switching Strategy

Difficulty tolerating one endocrine therapy does not necessarily mean you will have the same experience with every endocrine therapy.

This is where a switching strategy can be extremely helpful.

There are three aromatase inhibitors—letrozole, anastrozole, and exemestane—and some patients tolerate one considerably better than another.

Your oncologist may recommend switching from one aromatase inhibitor to another.

For some patients, switching from an aromatase inhibitor to tamoxifen may be appropriate.

In selected situations, your oncologist may also recommend a brief treatment break to see whether a particular symptom actually improves off the medication before deciding what to do next.

There are also strategies for treating specific side effects, including joint symptoms, bone loss, hot flashes, vaginal and urinary symptoms, and other problems associated with estrogen deprivation.

The choice is not always:

“Stay miserable on this medication” versus “stop endocrine therapy forever.”

There may be several steps in between.

Quality of Life Matters

The benefits of endocrine therapy are important, but so is quality of life.

For some patients, side effects are mild and the decision to continue is straightforward.

For others, treatment significantly interferes with mobility, intimacy, sleep, work, exercise, or emotional well-being.

Those concerns should not simply be dismissed.

The goal should be to understand both sides of the equation:

What is the medication doing to reduce my risk of breast cancer recurrence?

And what is the medication doing to my quality of life?

The fear of medication side effects and the fear of cancer recurrence are both real. Neither should automatically be ignored.

Questions to Ask Before Stopping Endocrine Therapy

Before making a final decision, consider discussing these questions with your oncology team:

What was my original risk of recurrence?
What is my estimated risk now?
How much absolute benefit am I receiving from endocrine therapy?
What is my risk of late recurrence beyond five or ten years?
How long do you recommend that I take endocrine therapy, and why?
Could we treat the side effect that is bothering me most?
Could I briefly hold the medication and reassess my symptoms?
Could I switch from one aromatase inhibitor to another?
Could tamoxifen be an alternative for me?

Do my bone health, cardiovascular health, menopausal symptoms, or other medical conditions change the balance of benefits and risks?

The answers may make the decision considerably clearer.

The Bottom Line

Hormone-blocking therapy is one of the most effective tools we have for reducing recurrence of hormone receptor-positive breast cancer.

For stage IV breast cancer, endocrine-based treatment is generally continuous because ongoing systemic therapy is needed to keep metastatic disease under control.

For stages I–III breast cancer, endocrine therapy is usually taken for years after definitive treatment to reduce the risk of the cancer returning locally or somewhere else in the body.

For DCIS, endocrine therapy is commonly considered for about five years when used, primarily to reduce the risk of another breast cancer event.

But taking endocrine therapy for years can be difficult.

If you are thinking about stopping because of side effects, try not to make the decision based only on how you feel on your current medication.

First, understand your individual recurrence risk and the absolute benefit the medication is providing. Then discuss whether the side effects can be treated, whether a temporary break is appropriate, whether another aromatase inhibitor might be better tolerated, or whether switching to tamoxifen is an option.

Ultimately, the decision about how long to continue endocrine therapy belongs to you and your healthcare team.

The goal is not simply to keep you on a pill.

The goal is to find the best balance between protecting your future health and preserving your quality of life today.

This article is for educational and supportive purposes only and is not intended to provide medical advice, diagnosis, or treatment. Decisions about starting, stopping, switching, or interrupting endocrine therapy should be made with your licensed oncology team based on your individual diagnosis, recurrence risk, treatment history, side effects, and overall health.

Worried About the Cost of a Session?

We never want cost to be the reason someone faces a breast cancer diagnosis without support. If a session is not within reach for you right now, email us at info@myfriendmd.com and we will do what we can to help.

Book Now